Study Reveals Path Linking Stress and Heart Health

Cover-Image-PastedGraphic-3

Patients with more activity (the purple area throughout the image at right) in the brain’s center for stress and fear were more likely to have a heart attack or stroke, compared to patients with less activity (at left).

A Mount Sinai researcher has played a key role in tracing—for the first time—the mechanisms that link stress to cardiovascular events, like heart attack or stroke. Zahi A. Fayad, PhD, Director of the Translational and Molecular Imaging Institute at the Icahn School of Medicine at Mount Sinai, was co-senior author of a paper on the research, which was published January 12, 2017, in The Lancet. The work will be expanded in a five-year project, funded by a new $7 million grant from the National Institutes of Health (NIH).

The research found that people who had more activity in an area of the brain that regulates the body’s response to stress and fear, called the amygdala, were more likely to have a heart attack or stroke than those with less activity. The findings “provide more evidence of a heart-brain connection,” Dr. Fayad says. “It may seem obvious, but until now the evidence had not been shown. We had not seen the mechanistic link.”

The Lancet paper was based on two complementary studies. One study was led by the first author of the paper, Ahmed A. Tawakol, MD, Co-Director of the Cardiac MR PET CT Program at Massachusetts General Hospital in Boston. The study analyzed data from 293 people who from 2005 to 2008 underwent positron emission tomography–computed tomography (PET/CT) brain imaging, primarily for cancer screening, using a radiopharmaceutical called FDG that measures activity in the brain, vascular system, and bone marrow. Researchers found that over the next four years, 22 of the patients had cardiovascular events. In that group, many patients had initially shown a high level of activity in the amygdala and a greater amount of inflammation in the aorta, and in the bone marrow, where new blood cells are made. The latter two factors can contribute to atherosclerosis, the hardening and narrowing of the arteries, which increases the risk for heart disease. This pathway—from emotional stress to increased white blood cells to inflammation to atherosclerosis—has been identified in animals, but until now, not in humans.

Mount Sinai Hospital Photo © Robert Caplin

Zahi A. Fayad, PhD

The second study, conducted by Dr. Fayad’s team at the Translational and Molecular Imaging Institute, examined 13 people who were being treated for post-traumatic stress disorder at Mount Sinai’s Mood and Anxiety Disorders Program. These patients completed a questionnaire about their perceived stress levels and underwent FDG-PET/MR scans. The team found that the patients’ stress levels were linked to increased activity in the amygdala, as well as increased inflammation in the blood vessels.

In the new project, Dr. Fayad—as overall principal investigator—will work with Dr. Tawakol; the leaders of the Mood and Anxiety Disorders Program, Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System; and Program Director James Murrough, MD, Assistant Professor of Psychiatry, and Neuroscience; and others at Mount Sinai.

The project is seeking to study three groups of patients: 80 who are being treated for PTSD; 80 who are “resilient,” with past exposure to trauma but a low perceived level of stress; and 80 who have not been exposed to trauma. It will explore the possibility that alleviating stress could not just improve patients’ psychological sense of well-being, but also improve their physical atherosclerotic health. “In the future, chronic stress can be treated as a risk factor for cardiovascular disease,” Dr. Fayad says, “so we can screen for it and manage it like other risk factors.”

Cover-Image-PastedGraphic-3-b

 

 

 

 

 

Cover-Image-PastedGraphic-3-c

A patient with high activity in the amygdala also showed inflammation in the aorta (top right) and bone marrow in the spinal column (bottom right). Another patient with low activity in the amygdala showed little or no inflammation in the aorta (top left) and bone marrow (bottom left).

Mount Sinai Offers 3D Printing and Virtual Modeling Services for Clinicians and Researchers

MVI_8498.00_04_46_15.Still002-RT

Joshua B. Bederson, MD, with a 3D model and an interactive simulation of the skull of a patient with a large epidermoid tumor—tools he used in planning the patient’s surgery.

The Mount Sinai Health System recently launched the Medical Modeling Core, a collaboration led by the Department of Neurosurgery, where Mount Sinai clinicians can order 3D and virtual models that can be used to explain procedures to patients, plan surgeries, and even conduct trial runs.

“Our simulation, prototyping, and 3D printing resources developed here at Mount Sinai are rare for a medical institution,” says Joshua B. Bederson, MD, Professor and Chair of Neurosurgery for the Mount Sinai Health System, and Clinical Director of the Neurosurgery Simulation Core at the Icahn School of Medicine at Mount Sinai. “In conjunction with simulation, they also play an important role in the patient-consultation process.”

The team is led by Anthony B. Costa, PhD, Assistant Professor in the Department of Neurosurgery, Scientific Director of the Neurosurgery Simulation Core, and Director of the Medical Modeling Core. Dr. Costa has developed digital tools to expedite the process of turning radiological data into 3D models and interactive, virtual modeling. The work is done rapidly—“in days, as opposed to weeks,” Dr. Costa says—and at a significantly lower cost than outside vendors. Recent models include brain tumors with surrounding vasculature and cranial nerves, spine modeling for the correction of severe scoliosis, and pelvic models for the planning of total hip replacement.

“When patients come in and are told they require a surgical procedure, it is often difficult for them to have a clear picture of what is going on in their own body,” Dr. Costa says. And 3D printing enables patients to pick up a model of the area affected, as the physician explains their condition and how the surgical procedure will work. “This offers patients confidence about what is about to happen to them,” Dr. Costa says. “We have found this to be a very successful approach.”

Mount Sinai clinicians and researchers who are interested in Medical Modeling Core services may visit icahn.mssm.edu/medicalmodeling or contact holly.oemke@mountsinai.org.

Why the Benefits of Hepatitis C Drug Therapies Outweigh the Risks

1770543_Dieterich_Douglas_ 1

Douglas Dieterich MD, Professor, Department of Medicine, Division of Liver Diseases, Director of the Institute for Liver Medicine, Mount Sinai Health System

Guest blog written by Douglas Dieterich MD, Professor, Department of Medicine, Division of Liver Diseases, Director of the Institute for Liver Medicine, Mount Sinai Health System

Viral hepatitis is liver inflammation caused by an infection with one of several different hepatitis viruses. According to Centers for Disease Control and Prevention (CDC), more than five million people in the United States live with some form of the disease—with the World Health Organization estimating 400 million affected worldwide. (more…)

Pin It on Pinterest